Ivosidenib is the first-in-class FDA approval for IDH1 mutation-harboring acute myeloid leukemia.
Clinical stage determined by the Binet staging system could be an accurate response surrogate among patients with chronic lymphocytic leukemia.
A large, long-term study found a 97% event-free survival rate at 18 months.
For the single-treatment STAT2 phase 2 study, researchers enrolled 96 Japanese patients with chronic myeloid leukemia who had achieved a deep molecular response during the consolidation phase of treatment with nilotinib.
Individuals at high risk of developing AML can be identified years before symptoms appear, a new study reports.
Investigators sought to evaluate the efficacy of enasidenib among older patients with untreated acute myeloid leukemia, a population that is associated with poor therapeutic outcomes.
Disease recurrence remained low among patients with CML who reduced or discontinued TKI therapy after achieving major response.
Researchers randomly assigned previously untreated patients with CD20-positive CLL to receive obinutuzumab plus chlorambucil, rituximab plus chlorambucil, or chlorambucil alone.
The effect of CAR-T therapy in acute myeloid leukemia has yet to be fully explored.
ENESTfreedom Study Reports Durable Treatment-Free Remission in Chronic Myeloid Leukemia After 96 WeeksJune 25, 2018
Nearly half of patients with CML who achieved a deep molecular response following treatment with nilotinib remained in remission for 96 weeks.
CLL/SLL characterized by del(17p) — a cytogenetic abnormality that develops over the course of the disease — is difficult to treat and responds very poorly to chemoimmunotherapy.
Bosutinib is a dual Src/Abl tyrosine kinase inhibitor approved for newly diagnosed CP-CML and relapsed/refractory CML.
Data from a previous study supports treatment-free remission as a new treatment goal for patients with chronic-phase chronic myeloid leukemia.
There are some clinical data to support a potential for increased risk of additional solid organ malignancies in patients with CML.
Men have approximately double the incidence rate, are more likely to have progressive and treatment-resistant disease, and have a poorer prognosis compared with women with CLL.
Because most patients with CML are adults, there are no established treatment guidelines and many clinicians apply adult guidelines to their pediatric patients.
Previous studies have shown that first-line therapy with nilotinib, as well as switching to nilotinib after prolonged imatinib, may lead to higher rates of deep molecular response in chronic myeloid leukemia.
Targeted therapies among patients with chronic myeloid leukemia have improved over time, leading to patients achieving high rates of deep molecular response — a prerequisite criteria for tyrosine kinase inhibitor discontinuation.
Dasatinib 100 mg is currently approved for chronic myeloid leukemia but has been associated with high rates of adverse events.
Researchers determined 3 levels of somatic mutation clearance based on VAF of residual mutations at CR.
Get the latest treatment regimens for acute myeloid leukemia (AML), such as induction therapy, consolidation therapy, and more.
Patients with CLL may have both disease-associated and systemic treatment-associated immune dysfunction, leaving them vulnerable to infection.
The FDA is reviewing a New Drug Application, which is requesting full approval for CLL/SLL and accelerated approval for follicular lymphoma.
Findings from previous studies suggests that multiparameter flow cytometric minimal residual disease may be used to predict outcomes in acute myeloid leukemia.
One study's results may be especially relevant for patients eligible for treatment discontinuation.
Voxtalisib is a potent inhibitor of 4 PI3K isoforms (p110α, p110β, p110γ, and p110δ) and a weaker inhibitor of mTOR.
Patients one year or older are now eligible to receive the drug.
Patients in the venetoclax arm had a grade 3 or 4 tumor lysis syndrome rate of 3.1%.
Recently published findings suggest that patients with CML, particularly men, have a 30% higher risk of developing secondary cancers; however the cause of this increased risk is unclear.
A subset of patients with chronic-phase CML in the ENESTfreedom study maintained treatment-free remission for at least 96 weeks after being treatment with frontline nilotinib.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- FDA Approves Ivosidenib for IDH1-Mutated Relapsed/Refractory Acute Myeloid Leukemia
- Clinical Stage at First Response May Predict Outcomes in Chronic Lymphocytic Leukemia
- Exercise and Cancer
- Increased Body Mass Index May Be Predictive of Recurrence, Progression in Bladder Cancer
- Aspirin, Non-Aspirin NSAID-Use May Improve Survival Outcomes in Ovarian Cancer